

February 27, 2012



Navidea Biopharmaceuticals to Announce Fourth-Quarter and Full-Year 2011 Financial Results on Thursday, March 1, 2012

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB) a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the Company will host a conference call and live audio webcast at 8:00 a.m. ET on Thursday, March 1, 2012 to provide a business update and discuss its fourth-quarter and full-year 2011 financial and operational results.

Investors and the public are invited to listen to a live webcast of the call. If you are unable to join the live call, an archived version of the webcast will be available until March 15, 2012. The conference call can be accessed as follows:

CONFERENCE CALL INFORMATION

TO PARTICIPATE LIVE:

Date: March 1, 2012

Time: 8:00 am ET

Toll-free (U.S.) Dial in # : 877) 407-8033

International Dial in # : (201) 689-8033

TO LISTEN TO A REPLAY:

Available until: March 15, 2012

Toll-free (U.S.) Dial in # : (877) 660-6853

International Dial in # : (201) 612-7415

Replay passcode:

Account #: 286

Conference ID #: 390060

About Navidea Biopharmaceuticals, Inc.

Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing three radiopharmaceutical agent platforms – Lymphoseek[®], AZD4694 and RIGScan[™] – to help identify the sites and

pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and ultimately patient care. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company's pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.

Navidea Biopharmaceuticals, Inc.
Brent Larson, 614-822-2330
Sr. VP & CFO

Source: Navidea Biopharmaceuticals, Inc.